0001564590-21-053727.txt : 20211103 0001564590-21-053727.hdr.sgml : 20211103 20211103070541 ACCESSION NUMBER: 0001564590-21-053727 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 211373677 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-8k_20211103.htm 8-K eypt-8k_20211103.htm
false 0001314102 0001314102 2021-11-03 2021-11-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2021

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

000-51122

 

26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of

each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 3, 2021, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. 

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1

  

Press Release of EyePoint Pharmaceuticals, Inc., dated November 3, 2021

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EyePoint Pharmaceuticals, Inc.

 

 

Date: November 3, 2021

 

By:

 

/s/ George O. Elston

 

 

Name:

 

George O. Elston

 

 

Title

 

Chief Financial Officer and Head of Corporate Development

 

 

 EX-99.1 2 eypt-ex991_10.htm EX-99.1 eypt-ex991_10.htm

 

Exhibit 99.1

 

EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –

– Topline data for DAVIO trial to be presented at American Academy of Ophthalmology (AAO) 2021 Annual Meeting on November 13, 2021 -

– Net product revenues of $8.6 million versus $5.8 million in Q3 2020, a 49% increase –

– Management to host a conference call and webcast today at 8:30 AM ET –

 

WATERTOWN, Mass., November 3, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate developments.

“We continue to advance our pipeline, announcing positive 3-month safety data for all dose levels in our Phase 1 DAVIO trial at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting held in October.  We look forward to presenting topline interim safety and efficacy data for the DAVIO trial as a late breaker presentation during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting on November 13.  In October, we also announced preliminary data from our YUTIQ® CALM real-world registry study at ASRS, which allows us to better understand the posterior segment uveitis patients we serve.” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals.

Ms. Lurker continued, “Our commercial team continues to perform with solid year over year revenue growth for both DEXYCU and YUTIQ, despite a continued impact on demand caused by the COVID-19 pandemic.”

R&D Highlights

 

•

In October 2021, the Company reported positive 3-month safety results for all dose levels from its ongoing DAVIO trial of EYP-1901 for wet-AMD at the ASRS 2021 Annual Meeting. Adverse events (AEs) reported in the 3-month safety results were all mild to moderate in severity with no ocular serious adverse events (SAEs) or drug-related systemic SAEs reported.  In addition, there were no reported AEs related to significant intraocular inflammation, best corrected visual acuity (BCVA) reduction, or elevation of intra-ocular pressure (IOP). Further, no events of endophthalmitis, retinal detachment, or migration into the anterior chamber were reported.

 

 

 

•

In September 2021, the Company announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD was selected for presentation at the AAO 2021 Annual Meeting.  The presentation is scheduled for November 13, 2021.

 

•

In October 2021, the Company reported preliminary data from its ongoing YUTIQ® CALM real-world registry study at Retina Society and ASRS. The study is collecting data on patients who have received the fluocinolone acetonide intravitreal implant 0.18 mg and includes patients 18 years of age and older with a diagnosis of chronic noninfectious uveitis affecting the posterior segment.  Interim baseline data on patients in the registry as of August 2021 show that most patients enrolled to date at entry suffer from uveitis of substantial disease duration (mean 57 months, or 4.75 years) and also have a variety of etiologies, mostly unknown, and previous treatments in their medical history. Following injection with YUTIQ® most patients have experienced relatively controlled intraocular inflammation as measured by anterior chamber cell count and vitreous haze.

Recent Business Highlights

 

•

On November 1, 2021, the Company appointed Jay S. Duker, M.D. as its Chief Operating Officer. In his new role, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing. Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after serving as an independent member of the EyePoint Board of Directors since 2016. Dr. Duker has spent over 30 years in academic ophthalmology, and for the past 21 years served as Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, a position he relinquished to join EyePoint full time.

Commercial Performance in Third Quarter 2021

 

•

Net product revenue for YUTIQ® and DEXYCU was $3.9 million and $4.7 million, respectively.

 

•

Customer demand of approximately 560 units of YUTIQ and approximately 13,100 units for DEXYCU, compared to approximately 540 units and 10,900 units, respectively for Q2 2021 customer demand.

Review of Results for the Third Quarter ended September 30, 2021

For the quarter ended September 30, 2021, total net revenue was $9.1 million compared to $15.7 million for the quarter ended September 30, 2020. Net product revenue for the quarter was $8.6 million, compared to net product revenues for the quarter ended September 30, 2020 of $5.8 million.

Net revenue from royalties and collaborations for the quarter ended September 30, 2021 totaled $0.5 million compared to $9.9 million in the corresponding period in 2020.  

Operating expenses for the quarter ended September 30, 2021 totaled $24.4 million versus $17.7 million in the prior year period. This increase was primarily due to a $4.4 million increase in R&D expense, a $2.1 million increase in sales and marketing expense, a $0.3 million increase in G&A expense and offset by a $0.1 million decrease in cost of sales. Non-operating expense, net, totaled $1.4 million and net loss was $16.7 million, or ($.58) per share, compared to a net loss of $3.8 million, or ($.30) per share, for the prior year period.

 

 

Cash and cash equivalents at September 30, 2021 totaled $119.7 million compared to $44.9 million at December 31, 2020.

Financial Outlook
We expect the cash on hand at September 30, 2021 and expected net cash inflows from our product sales will enable us to fund our current and planned operations through the end of 2022.

Conference Call Information
EyePoint will host a conference call today, at 8:30 AM ET to discuss the results for the third quarter ended September 30, 2021 and recent operational developments. To access the conference call, please dial (877)-312-7507 from the U.S. and Canada or (631)-813-4828 (international) at least 10 minutes prior to the start time and refer to conference ID 9396615. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website.

About EYP-1901

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 combines a bioerodible formulation of EyePoint’s proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. Preclinical studies of EYP-1901 have shown anti-VEGF activity in disease models of ocular neovascularization and no serious safety issues were observed. EYP-1901 is initially being developed as a treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.

About YUTIQ®

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, and was approved by the FDA on October 12, 2018. A link to the full product label is available on the YUTIQ website at: https://yutiq.com/downloads/US-YUT-2100035%20YUTIQ%20Prescribing%20Information-2021.pdf.

 

About EyePoint Pharmaceuticals, Inc. 

EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

 

 

 

 

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

 

 

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact:

Amy Phillips

Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com

 

 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

8,587

 

 

$

5,758

 

 

$

24,127

 

 

$

14,151

 

License and collaboration agreements

 

 

159

 

 

 

9,535

 

 

 

594

 

 

 

11,590

 

Royalty income

 

 

313

 

 

 

402

 

 

 

674

 

 

 

1,565

 

Total revenues

 

 

9,059

 

 

 

15,695

 

 

 

25,395

 

 

 

27,306

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales, excluding amortization of acquired

   intangible assets

 

 

1,825

 

 

 

1,882

 

 

 

5,144

 

 

 

3,363

 

Research and development

 

 

8,498

 

 

 

4,090

 

 

 

19,582

 

 

 

12,219

 

Sales and marketing

 

 

7,374

 

 

 

5,269

 

 

 

19,692

 

 

 

19,483

 

General and administrative

 

 

6,060

 

 

 

5,796

 

 

 

16,358

 

 

 

14,949

 

Amortization of acquired intangible assets

 

 

615

 

 

 

615

 

 

 

1,845

 

 

 

1,845

 

Total operating expenses

 

 

24,372

 

 

 

17,652

 

 

 

62,621

 

 

 

51,859

 

Loss from operations

 

 

(15,313

)

 

 

(1,957

)

 

 

(37,226

)

 

 

(24,553

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other income, net

 

 

6

 

 

 

(4

)

 

 

286

 

 

 

58

 

Interest expense

 

 

(1,388

)

 

 

(1,840

)

 

 

(4,110

)

 

 

(5,430

)

Gain on extinguishment of debt

 

 

—

 

 

 

—

 

 

 

2,065

 

 

 

—

 

Total other income (expense), net

 

 

(1,382

)

 

 

(1,844

)

 

 

(1,759

)

 

 

(5,372

)

Net loss

 

$

(16,695

)

 

$

(3,801

)

 

$

(38,985

)

 

$

(29,925

)

Net loss per common share - basic and diluted

 

$

(0.58

)

 

$

(0.30

)

 

$

(1.42

)

 

$

(2.44

)

Weighted average common shares outstanding -

   basic and diluted

 

 

28,766

 

 

 

12,794

 

 

 

27,429

 

 

 

12,277

 

 

 

 

 

 

 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

119,710

 

 

$

44,909

 

Accounts and other receivables, net

 

 

13,602

 

 

 

9,453

 

Prepaid expenses and other current assets

 

 

3,892

 

 

 

3,419

 

Inventory

 

 

4,571

 

 

 

5,337

 

Total current assets

 

 

141,775

 

 

 

63,118

 

Operating lease right-of-use assets

 

 

2,402

 

 

 

2,610

 

Intangible assets, net

 

 

23,364

 

 

 

25,209

 

Other assets

 

 

710

 

 

 

780

 

Total assets

 

$

168,251

 

 

$

91,717

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

18,102

 

 

$

13,256

 

Deferred Revenue

 

 

1,035

 

 

 

945

 

Other current liabilities

 

 

796

 

 

 

687

 

Total current liabilities

 

 

19,933

 

 

 

14,888

 

Long-term debt

 

 

36,396

 

 

 

37,977

 

Deferred revenue - noncurrent

 

 

14,792

 

 

 

15,616

 

Operating lease liabilities - noncurrent

 

 

2,019

 

 

 

2,330

 

Other long-term liabilities

 

 

2,363

 

 

 

2,365

 

Total liabilities

 

 

75,503

 

 

 

73,176

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Capital

 

 

641,572

 

 

 

528,380

 

Accumulated deficit

 

 

(549,665

)

 

 

(510,680

)

Accumulated other comprehensive income

 

 

841

 

 

 

841

 

Total stockholders’ equity

 

 

92,748

 

 

 

18,541

 

Total liabilities and stockholders’ equity

 

$

168,251

 

 

$

91,717

 

 

 

 GRAPHIC 3 geatbg5yw1nu000001.jpg GRAPHIC begin 644 geatbg5yw1nu000001.jpg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eypt-20211103.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 eypt-20211103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 6 eypt-20211103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 eypt-8k_20211103_htm.xml IDEA: XBRL DOCUMENT 0001314102 2021-11-03 2021-11-03 false 0001314102 8-K 2021-11-03 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 03, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2021
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Trading Symbol EYPT
Entity Emerging Growth Company false
Entity File Number 000-51122
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Entity Incorporation, State or Country Code DE
Title of 12(b) Security Common Stock, par value $0.001
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports eypt-8k_20211103.htm eypt-20211103.xsd eypt-20211103_lab.xml eypt-20211103_pre.xml eypt-ex991_10.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eypt-8k_20211103.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "eypt-8k_20211103.htm" ] }, "labelLink": { "local": [ "eypt-20211103_lab.xml" ] }, "presentationLink": { "local": [ "eypt-20211103_pre.xml" ] }, "schema": { "local": [ "eypt-20211103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20211103", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20211103.htm", "contextRef": "C_0001314102_20211103_20211103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20211103.htm", "contextRef": "C_0001314102_20211103_20211103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyepointpharma.com/20211103/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-053727-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-053727-xbrl.zip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